EMBC vs LFUS vs CTS vs UTMD vs NVCR

For growth investors, Littelfuse, Inc.

(LFUS) is the stronger pick with 8. 9% revenue growth year-over-year, versus -5. 8% for Utah Medical Products, Inc. (UTMD). Embecta Corp. (EMBC) offers the better valuation at 2. 2x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate Littelfuse, Inc. (LFUS) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Embecta Corp.

(EMBC) is the cheapest at 2. 2x versus CTS Corporation at 27. 3x. On forward P/E, Embecta Corp. is actually cheaper at 1. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CTS Corporation wins at 1. 58x versus Utah Medical Products, Inc. 's 3. 03x — a reasonable growth-adjusted valuation.

Over the past 5 years, CTS Corporation (CTS) delivered a total return of +83.

2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LFUS returned +317. 6% versus EMBC's -87. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Utah Medical Products, Inc.

(UTMD) is the lower-risk stock at 0. 55β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 298% more volatile than UTMD relative to the S&P 500. On balance sheet safety, Utah Medical Products, Inc. (UTMD) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Littelfuse, Inc.

(LFUS) is pulling ahead at 8. 9% versus -5. 8% for Utah Medical Products, Inc. (UTMD). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -172. 5% for Littelfuse, Inc.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Utah Medical Products, Inc.

(UTMD) is the more profitable company, earning 29. 3% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 29. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMBC leads at 30. 5% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, CTS Corporation (CTS) is the more undervalued stock at a PEG of 1. 58x versus Utah Medical Products, Inc. 's 3. 03x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Embecta Corp. (EMBC) trades at 1. 3x forward P/E versus 33. 8x for Littelfuse, Inc. — 32. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EMBC: 233. 3% to $12. 00.

In this comparison, EMBC (16.

5% yield), UTMD (1. 9% yield), LFUS (0. 7% yield), CTS (0. 3% yield) pay a dividend. NVCR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Utah Medical Products, Inc.

(UTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 55), 1. 9% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UTMD: +19. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EMBC (Healthcare) and LFUS (Technology) and CTS (Technology) and UTMD (Healthcare) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EMBC is a small-cap deep-value stock; LFUS is a mid-cap quality compounder stock; CTS is a small-cap quality compounder stock; UTMD is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. EMBC, LFUS, UTMD pay a dividend while CTS, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.